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Abstract 
SLIT2 has been classified as a major tumour suppressor gene due to its frequent inactivation in different cancer 
types. However, alterations of SLIT2 expression and relation to patient outcomes in diffuse large B-cell lymphoma 
(DLBCL) remain undefined.  The aim of this study was to investigate the expression and the methylation status of 
SLIT2 gene as well as its relation to patient outcomes in DLBCL. Immunohistochemical (IHC) staining was carried 
out to detect the expression of SLIT2 in a series of 108 DLBCL cases. Re-analysis of previously published dataset 
(GSE10846) that measured gene expression in DLBCL patients who had received CHOP or R-CHOP therapy was 
performed to identify associations between SLIT2 and patients survival. Laser capture microdissection was 
performed to isolate GC B cells and DLBCL primary tumor cells. Bisulfite treatment and methylation-specific PCR 
(MSP) analysis were done to assess SLIT2 promotor methylation status. The expression of SLIT2 protein was 
reduced in a subset of DLBCL cases and this was significantly correlated with advanced clinical stage (p= 0.041) 
and was an independent predictor of worse overall survival (OS) (p= 0.012). Re-analysis of published gene 
expression data showed that reduced SLIT2 mRNA expression was significantly correlated with worse OS in  R-
CHOP-treated ABC DLBCL patients (p= <0.01). Hypermethylation of the SLIT2 promotor was significantly 
correlated with low SLIT2 expression (p=0.009). Our results provide a novel evidence of reduced expression of 
SLIT2 that is associated with promoter hypermethylation and adverse outcomes in patients with DLBCL.  
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Introduction 
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease with distinct molecular features and 
clinical behavior [1]. It is the most common of the non-Hodgkin lymphomas [2]. About 30-40 percent of the non-
Hodgkin lymphomas are DLBCL. Based on gene expression profiling, two main classes of DLBCL can be 
identified, these are the germinal center B-cell (GCB) and the activated B-cell like subtypes (ABC) with a small 
percentage (10-15%) being un-classifiable [3, 4]. 
DLBCL is usually an aggressive cancer, with a median survival of less than 12 months in untreated 
patients. Since the 1970s, the standard treatment has been the CHOP regimen consisting of adriamycin, vincristine, 
and cyclophosphamide [5]. Use of this regimen is associated with around 40% progression-free survival and 50% 
long-term survival [6].  There has been a considerable improvement in the prognosis of DLBCL within the last few 
years, mainly due to the inclusion of rituximab, an anti-CD20 monoclonal antibody [7]. Notwithstanding these 
notable achievements, a sizable percentage of patients have refractory disease or will relapse reducing their chances 
of survival [8].  
The pathogenesis of DLBCL is complex involving interactions between genomic and epigenomic changes 
[9,10]. SLIT2 has been classified as a major tumour suppressor gene due to its frequent inactivation in different 
cancer types, including deletion or hyper-methylation of its promoter [11,12]. SLIT2 plays a role in the suppression 
of tumour growth [13,14]. via the regulation of WKHȕ-catenin and PI3-K signaling pathways leading to enhancement 
of ȕ-catenin and E-cadherin mediated cell-cell adhesion [15].  
In hematolymphoid malignancies, only in leukemias and mantle cell lymphoma, few reports are available 
for the role of SLIT2 and its main receptor ROBO1 [16±18]. These reports showed frequent SLIT2 methylation in 
leukemia cell lines, also in acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) primary 
samples [17]. Moreover, the expression of SLIT2 was restored after treating ALL lines with the demethylating agent 
(5-aza-2ƍ-deoxycytidine) [17]. In Mantle cell lymphoma, ROBO1 displayed a high level of methylation, which 
correlated well with its low mRNA expression [16, 18], also correlated with aggressive clinciopathological features 
and shorter survival [18]. Here, we have studied the expression and the methylation status of SLIT2 gene as well as 
its relation to patient outcome in DLBCL. 
 
Materials and Methods 
Tissue specimens 
This is a retrospective cohort study in which Formalin-fixed paraffin-embedded tissues were used  from 
108 DLBCL patients diagnosed between 1997 and 2012 at the University Hospital, Birmingham. Diagnosis was 
confirmed by histological review. Detailed clinical and follow-up data was available for all patients. Follow up 
ranged from 1- 180 months with a mean of 45 months. Based on the Hans algorithm, DLBCL were grouped by 
IHC into either GCB or ABC-DLBCL types [19]. The baseline pathologic and clinical characteristics of the patients 
are listed in Table 1. Different normal/reactive lymphoid tissues (tonsils and lymph nodes) obtained through  
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tonsillectomy or excision biopsy, fixed in formalin and embedded with paraffin,  were used for both positive and 
negative control as well as for GC B cells microdissection for the methylation analysis (see below).   
Immunohistochemistry 
Paraffin-embedded tissues from both DLBCL samples and normal lymphoid tissues were sectioned at a 
WKLFNQHVVRIȝPDQGSODFHGRQ;-tra Adhesive micro slides. The expression of SLIT2 protein was detected by IHC 
using Leica BOND-MAXTM autostainer (Leica Biosystems) according to the protocol instruction. In brief, the 
tissue sections were deparaffinized and then rehydrated through graded alcohols. Sections were immersed into 
preheated EDTA (PH 8.0) for 20 minutes. Endogenous peroxidase activity inhibited in 0.3% hydrogen peroxide, and 
non-specific binding sites blocked with normal goat serum at room temperature. Primary mouse monoclonal anti-
SLIT2 [Clone EPR2771; Abcam Ltd. 134166 USA; diluted at 1:800) was used for 1 hr. A cold PBS was used in 
place of the primary antibody for the negative control staining. 
Microdissection of GC B cells and DLBCL cells 
DLBCL cases were selected with variable SLIT2 staining intensity as well as GC B-cells from 
normal/reactive lymphoid tissues expressing strong SLIT2 staining.  A total of 6 unstained sections per each case 
ZHUHFXWDWȝP WKLFNQHVV and stained with Haematoxylin with available matched SLIT2 immunostained sections 
for each case.  Sections were placed onto membrane-covered slides for microdissection (PEN membrane slide, Carl 
Zeiss Ltd. Germany).  Using a PALM Microbeam microdissection (Carl Zeiss Ltd, Germany), laser capture 
microdissection was performed to capture GC B cells and DLBCL tumor cells from areas of which matched to the 
SLIT2 stained sections. Microdissected tissues were put into PALM adhesive cap (Carl Zeiss Ltd.) tubes for further 
methylation analysis. 
Analysis of SLIT2 expression 
The entire tumour section was scanned at low power to survey overall staining intensity in DLBCL tumour 
cells. SLIT2 protein was found to be expressed in both tumour cell cytoplasm and the membrane. The intensity was 
judged by the comparing the intensity between tumour and GCs of normal lymphoid tissue (tonsillar/lymph nodal 
tissue as an external positive control or residual GCs in the affected lymph node as an internal positive control).  
The expression intensity was scored as follows: 0 =negative, 1 = weak, 2 = moderate, comparable to 
normal germinal centers and 3 = strong, presence of cells with staining obviously stronger than in normal GCs. 
Staining percentage was scored 4 (if greater than 75% of tumour cells were positive), 3 (50-75%), 2 (25-50%), or 
1(< 25%). The staining ZDVJUDGHGDV³ORZH[SUHVVLRQ´LI  staining intensity multiplied by percentage was less than 
or equal to 4 [20, 21]. 
Re-analysis of gene expression data   
A previously published dataset (GSE10846) that had measured gene expression in DLBCL patients 
who received CHOP or R-CHOP therapy [22] was downloaded from GEO 
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(https://www.ncbi.nlm.nih.gov/geo/). The %LRFRQGXFWRU SURMHFW¶V affy package was used to conduct a probe 
level quantile normalization [23] and robust multi-array analysis [24] on the raw CEL files. The R survival 
package was used to perform survival analysis (http://www.r-project.org/), including log-rank test with samples 
split by median SLIT2 expression. 
Bisulfite treatment and methylation-specific PCR (MSP) analysis  
DNA was extracted from the microdissected samples using QIAamp DNA FFPE Tissue Kit (Catalogue no. 
56404). Microdissected cells were placed in proteinase K digestion solution, then incubated at 90°C. Residual 
contaminants were washed away. DNA was then eluted in Buffer ATE. Purified DNA was checked on Nanodrop 
spectrophotometer. DNA was stored at -200C. 
Bisulfite modification of genomic DNA was carried out as described previously [25, 26]. 50 ng of 
bisulfited DNA for each sample was used for methylation-specific PCR (MSP) analysis. Multiple methylated primer 
sets targeting SLIT2 promoter were designed and tested. The best pair (m5/m7) with clear methylation band, 
inversely correlated with expression, and not amplifying any not-bisulfited DNA, was chosen. MSP primer set used 
in the study was:  SLIT2m5 ¶-GATCGGTTTAGGTTGCGG C; SLIT2P ¶-
AACAACTAAACATAACGCGCG.  MSP was performed for 38 cycles using AmpliTaq Gold® DNA Polymerase 
(Thermo Fisher Scientific) [25-27]. 
 
Statistical Methods 
Data were analyzed using IBM SPSS advanced statistics (Statistical Package for Social Sciences), version 
23 (SPSS Inc., Chicago, IL). Numerical data was described as median and interquartile range or range or mean and 
standard deviation as appropriate, while qualitative data were described as number and percentage. Chi-square 
(Fisher's exact) test was used to examine the relation between qualitative variables as appropriate. Survival analysis 
was done using the Kaplan-Meier method. Comparison between two survival curves was done using the log rank 
test. Multivariate analysis was done by Cox regression model to test for independent prognostic effects of 
statistically significant variables on univariate level with calculating hazard ratio and its 95% confidence interval. A 
p-value less than 0.05 was considered statistically significant. All tests were two tailed. Overall survival (OS) was 
calculated from date of diagnosis till date of death or last follows up. Event free survival (EFS) was calculated from 
date of treatment till date of relapse, death or last known follow up. 
 
Results  
Pattern of SLIT2 protein expression in normal lymphoid tissue and DLBCL 
Immunohistochemical analysis of SLIT2 was performed for both normal lymphoid tissue (tonsil/lymph 
nodes) and primary DLBCL. In normal lymphoid tissue, high SLIT2 expression was restricted to the germinal 
centers with only few inter-follicular lymphocytes showing low SLIT2 expression [Figure 1a&b].  SLIT2 was 
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located in both the cytoplasm and membrane of DLBCL tumour cells. Different intensities of SLIT2 protein 
expression were observed among different cases; 41/108 cases (38%) showed high expression (SLIT2 intensity 
multiplied by the percentage >4), 66/108 (61.1%) had low expression (SLIT2 intensity multiplied by the percentage 
 4). Only one case (1/108, 0.9%) was negative (/RZH[SUHVVLRQ). Figure 1c&d show representative DLBCL 
cases with different levels of SLIT2 protein expression.  Of the 108 cases, 49 (45.4%) were of GCB type, while 58 
(53.7%) cases were of ABC-DLBCL type. One case was unclassifiable due to inconclusive IHC results. 55.1% (27 
cases) of GCB DLBCL and 65.5% (38 cases) of the ABC-DLBCL showed low SLIT2 expression. There was no 
significant correlation between subtype and SLIT2 protein expression (p= 0.27).  
Association between SLIT2 protein expression and clinicopathological features  
In our study, a significant correlation between low SLIT2 intensity and advanced clinical stage was found 
(stages 3&4 vs 1&2; p=0.041). There was a tendency for cases with low SLIT2 expression to be associated with the 
poor prognostic group as defined by the Revised International Prognostic Index (R-IPI) (p=0.099). No significant 
relationships between SLIT2 protein expression and other parameters were found [Table 2]. 
Impact of SLIT2 protein expression on the survival of DLBCL patients 
SLIT2(?protein expression was then assessed for its impact on patient outcome. A univariate Kaplan-Meier 
(K-M) analysis revealed a significant reduction in overall survival (OS) for DLBCL patients with low 
SLIT2ࣟprotein, with a median of 28 months, while the median survival was not reached in patients with strong 
SLIT2 H[SUHVVLRQ(?(p= 0.044) [Figure 2A]. In a multivariate analysis, SLIT2 was an independent significant predictor 
of OS (p= 0.012). Although the median EFS was only 12.6 months for patients with low tumour expression of 
SLIT2, compared with 88.9 months for those with strong SLIT2 expression, though this difference was not 
significant (p= 0.108), [Figure 2B]. We also evaluated the impact of SLIT2 protein expression on outcome 
separately for patients with each of the DLBCL subtypes. We found no correlation between SLIT2 protein 
expression and OS or EFS in patients with either GC- (p= 0.26 and p= 0.35, respectively) or ABC-DLBCL (p= 0.26 
and p= 0.31, respectively). 
 
SLIT2 gene expression predicts survival in DLBCL (ABC subtype) patients treated with R-CHOP  
To further explore the potential effects of SLIT2 expression on outcome we took advantage of the dataset 
previously published by Lenz et al (2008) (GSE10846) that had measured gene expression in the tumour tissues of 
181 DLBCL patients treated with either CHOP or R-CHOP and which had used microarray gene expression to 
define subtype (Lenz et al. 2008). We found that low SLIT2 mRNA expression was significantly correlated with 
worse OS in R-CHOP-treated ABC DLBCL patients (p= <0.01) [Figure 3]. SLIT2 expression was not significantly 
correlated with OS or EFS in patients with the GC subtype.  
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Methylation of the SLIT2 promotor in DLBCL  
We measured SLIT2 promoter methylation in 26 DLBCL cases with different SLIT2 protein expression as 
well as microdissected GC B cells with high SLIT2 expression, 14/26 (54%) DLBCL had low SLIT2 protein 
expression and 12/26 (46%) strong expression.  
Higher SLIT2(? methylation (strong/moderate) was found in cases with reduced SLIT2 protein expression, 
and that was statistically significant (Fisher's exact test, p= 0.009). In samples with low/negative SLIT2 expression, 
13/14 (92.9%) had a strong/moderate-methylation status. On the other hand, among samples with higher SLIT2 
expression, 7/12 (58.3%) had weak/un-methylation status, while 5/12 (41.7%) had strong/moderate-methylation 
status [Figure 4A]. In contrast the microdissected GC B cells with strong SLIT2 protein expression, showed 
unmethylated SLIT2 gene [Figure 4B]. In this small series there was no statistically significant correlation between 
SLIT2 methylation and DLBCL subtypes (7/18 ABC-DLBCL and 4/8 GCB DLBCL had weak/un-methylation 
status; p= 0.65).    
 
DISCUSSION 
The SLIT family of genes is large extracellular matrix-secreted and membrane-associated glycoproteins. 
SLIT2 is known to function through its two main receptors Robo1 and Robo4. Robo1 is mainly expressed in cancer 
cells [28].  
The present study aimed to identify if SLIT2 might be a potential tumour suppressor also in DLBCL. After 
careful search of existing literatures, no such study has yet been reported in DLBCL. Our results show that a subset 
of DLBCL is characterized by reduced SLIT2 expression correlated significantly with promotor hypermethylation. 
Furthermore, reduced SLIT2 expression was also associated with poor prognosis, suggesting that SLIT2 might serve 
as a prognostic biomarker in DLBCL patients.  
In our study, reduced expression of SLIT2 protein was correlated significantly with advanced clinical stage 
(p= 0.041). Moreover, a significant reduction in OS of DLBCL patients was correlated with low expression 
RI(?6/,7(?SURWHLQ(?3(? 7Kis has been supported by multivariate analysis where poor survival was associated 
with lower SLIT2 expression (p=0.012). 
Consistent with our data, several studies indicate that inactivation of the SLIT/ROBO1 pathway is 
important for cancer development and that its low expression is associated with a poor prognosis [13, 20]. Thus, 
Tseng et al. (2015), found that low SLIT2 expression is correlated with late stage and with poor OS and DFS in 
oesophageal cancer patients [21], effects which might be explained by their observation that cancer cell motility is 
reduced when SLIT2 is stably overexpressed. These observations were confirmed by Kim et al. (2008), who found 
that SLIT2 expression was decreased or abolished in human oesophageal squamous cell carcinomas (SCCs) 
compared to normal tissues as detected by in situ hybridization [29]. Low expression of SLIT2 also increased cell 
migration in lung cancer and invasive cervical cancer [30,31]. The underlying mechanism is that inactivation of the 
SLIT2-ROBO1 pathway enhances cell migration through accumulation of activated Cdc42 (a member of the Rho-
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family of GTPases ), resulting in loss of the interaction between E-cadherin and B-catenin and the inactivation of 
EGFR degradation [15, 21, 32,  33, 34]. 
 
SLIT2 protein can also inhibit the migration of endothelial cells which might explain the promotion of 
angiogenesis following SLIT2 loss [35]. Apoptosis was also shown to be increased and proliferation decreased in 
SLIT2-transfected tumours, suggesting another mechanism for SLIT2-mediated tumour suppression [29].  
Interestingly, Chang et al reported a correlation between low SLIT2 expression in the 
stromal fibroblasts  with lymph node metastasis in breast cancer, indicating an important role for the expression of 
SLIT2 in the tumour microenvironment on the progression of tumours [36].  
In our study, re-analysis of the published dataset that had measured mRNA expression among DLBCL 
patients treated with either CHOP or R-CHOP [22], revealed that downregulation of SLIT2 mRNA was significantly 
correlated with reduced overall survival of R-CHOP-treated ABC DLBCL patients. We did not find such an 
association in our IHC analysis possibly because of the smaller numbers of FFPE samples studied or because of the 
reported deficiencies in the correct delineation of gene expression sub-entities by IHC. 
It was evident that SLIT2 gene methylation was significantly correlated with its low protein expression in 
DLBCL, whereas normal GC B cells strongly expressed SLIT2 and lacked methylation of the promoter. Our results 
suggest that promoter methylation could explain the reduced expression of SLIT2 in DLBCL. In keeping with our 
findings, previous studies have reported that promoter hypermethylation is responsible for the down-regulation of 
SLIT2/ROBO1 signaling in various solid tumours, including breast, head and neck squamous cell carcinoma 
(HNSCC), cervical, oesophageal, hepatocellular carcinomas and gliomas, where it is also associated with poor 
prognosis [20,21,37,38,39].  In hematolymphoid malignancies, Dunwell et al (2009) found that SLIT2 was 
methylated in all ten leukemia cell lines analyzed, whilst DNA from peripheral blood and bone marrow from healthy 
control samples showed no SLIT2 methylation [17].  The expression of SLIT2 was restored after treating ALL lines 
with 5-aza-2'-deoxycytidine [17]. These findings suggest that reactivating the SLIT2 function by reversing 
epigenetic inactivation could represent a novel therapeutic opportunity to attenuate human cancer.  
In conclusion, the results of the present study indicate for the first time that reduced expression of SLIT2 
gene is associated with poorer patient outcomes in DLBCL. Furthermore, we have shown that SLIT2 protein down-
regulation correlates with promoter hypermethylation. The functional impact of reduced SLIT2 inhibition in 
DLBCL remains to be established.  
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Figure legends 
Fig. 1: SLIT2 protein expression in normal lymphoid tissue and DLBCL primary tumours (a) High SLIT2 
protein expression in the reactive GCs, also in normal squamous epithelium of the tonsil, with  low expression in 
few scattered  interfolliclular cells (Mag. 10x). (b)  Higher magnification of one of the GCs expressing high SLIT2 
protein. (c)  Example of high SLIT2 expression  (score 3) in DLBCL, sparing the residual normal/reactive 
lymphocytes. (d)  A representative case of DLBCL with low SLIT2 expression (score 1). 
Fig. 2:  Kaplan-Meier survival analysis for DLBCL cases expressing low/high SLIT2 protein. (A) Low SLIT2 
protein expression correlates with poor OS in DLBCL patients (p= 0.044).  (B) Patients with low SLIT2 protein or 
negative expression show difference in Event-free survival with a median of only 12.6 months as compared to 88.9 
median survival of patients experienced high SLIT2 protein, however that was not statistically significant (p= 
0.108). 
 
Fig. 3:  Re-analysis of a previously published gene expression dataset GSE10846. High SLIT2 gene expression 
correlates with better overall survival in R-CHOP treated ABC DLBCL patients (p= < 0.01). 
 
Fig. 4: Methylation-specific PCR (MSP) analysis of the SLIT2 promotor in microdissected GC B cells and 
DLBCL samples.  (A)  DLBCL cases with variable SLIT2 protein intensities as detected by IHC. Samples 
13 
 
highlighted in red express a low/negative SLIT2 protein.  Reduced SLIT2 protein expression correlates with 
promotor  methylation status (strong/moderate) (p=0.009).  (B)  GC B cells expressing high SLIT2 protein show un-
methylated status Methylated (OCI-LY3) and unmethylated (HEK293) cell lines were used as positive controls. M: 
methylated; U: unmethylated. 
 
 
 
          
 
  
 
 
 
 
